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Clinical characteristics of Kawasaki disease with 
sterile pyuria
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Purpose: Kawasaki disease (KD) is a systemic vasculitis and affects many organ systems. It often 
presents sterile pyuria, microscopic hematuria, and proteinuria due to renal involvement. The aims 
of this study were to define clinical characteristics of acute KD patients with pyuria and to analyze 
meaning of pyuria in KD. 
Methods: The medical records and laboratory findings including serum and urine test of 133 patients 
with KD admitted to Yeungnam University Hospital from March 2006 to December 2010 were reviewed 
retrospectively.
Results: Forty patients had sterile pyuria and their clinical characteristics including age, gender 
and body weight were not significantly different with those who did not have pyuria. Fever duration 
after treatment was significantly longer in KD patients with pyuria. Erythrocyte sedimentation rate, 
C-reactive protein and serum concentration of alanine aminotransferase were significantly higher in 
patients with pyuria. Hyponatremia and coronary artery lesion were seen more often in patients with 
pyuria but there was no significant difference. Also serum blood urea nitrogen was significantly higher 
in KD patients with pyuria. Urine β2-microglobulin was elevated in both patients groups and showed no 
difference between two groups. 
Conclusion: We found more severe inflammatory reaction in KD patients with pyuria. We also found 
elevation of some useful parameters like β2-microglobulin that indicate renal involvement of KD 
through the urine test. Careful management and follow up will need for KD patients with pyuria and it is 
necessary in the future to study the specific parameters for renal involvement of KD.
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Introduction
Kawasaki disease is an acute febrile disease frequently occurring mainly in infants 
and toddlers under the age of 5. This syndrome is characterized by a persistent fever 
and is not responsive to antibiotics for more than 5 days. Symptoms include poly­
morphous skin rash, nonpurulent conjunctivitis, inflammation of lips and the mouth, 
swollen hands and feet and cervical lymphadenopathy
1). Since Tomisaku Kawasaki 
first described 50 cases in Japan in 1967, numerous cases have been report  ed but the 
exact cause and pathogenesis are not completely known yet
2­4).
Kawasaki disease is a systemic vasculitis causing acute inflammation by invading 
mainly medium sized blood vessels
3) and may cause various symptoms by invading 
multiple organs. The findings accompanied by inflammation of the renal urinary 
tract are sterile pyuria, hematuria and proteinuria. It has been reported that the most 
common finding is sterile pyuria and accounts for 33% to 63% of total patients with http://dx.doi.org/10.3345/kjp.2013.56.1.13
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Kawasaki diseases
5­8). Many studies about parenchymal in­
vasion accompanied in Kawasaki disease have been con ducted. 
It has been reported that interstitial nephritis
9­12), acute renal 
failure
13­15), hemolytic uremic syndrome
16,17), and nephrotic 
syndrome
18) occurred in Kawasaki disease. In this study, we 
analyzed the implications of pyuria in the Kawasaki disease.
Materials and methods
One hundred thirty­three patients (male 82, female 51) who 
were diagnosed and treated with Kawasaki disease were di­
vided into a group of pyuria and a control group, and the 
comparative analysis on clinical characteristics and test 
results of each group was conducted.
Medical records of Kawasaki disease from March 2006 to 
December 2010 at the Department of Pediatrics at Yeungnam 
University Hospital were compared and analyzed retrospec­
tively. The diagnosis of Kawasaki disease was based on the 
criteria published by the American Heart Association in 
2004
19). In addition to that, even if someone did not meet the 
criteria, if Kawasaki disease was suspected clinically and other 
similar diseases were excluded, he or she was diagnosed with 
atypical Kawasaki disease.
Blood and urine samples were collected from all pati  ents 
in the acute phase admitted and the transthoracic echo­
cardiography was conducted. Blood and urine were collected 
before using high­dose gamma globulin and aspirin. With the 
cooperation of infant patients, mid­stream urine was col  lected. 
Without the cooperation, urine was collected from infant 
patients using a sterile urine collecting bag.
Case having five or more white blood cells at high magni­
fication on micro urine microscopy was defined as pyuria
20). 
Once all patients were divided into the group of pyuria with 
five or more white blood cells and the control group with less 
than 5, their gender, age and weight were compared. The total 
number of white blood cells, blood pigment, number of platelet, 
erythrocyte sedimentation rate (ESR), C­reactive protein (CRP), 
sodium, potassium, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, 
total protein and albumin, and estimated creatinine clearance 
were measured through blood tests. Microscopic hematuria 
(five or more red blood cells on micro urine microscopy), β2­
microglobulin (β2­MG) and total pro  teins were measured 
through urine collection. Estimated creatinine clearance was 
calculated with the Schwartz for  mula which is being used 
primarily in children
21). Blood and urine culture tests were 
conducted in all patients. If bacteria were homogenous in 
culture tests, it was excluded in this study.
We needed to determine whether or not the coronary 
arteries was normal based on the criteria published by Japan 
Kawasaki Disease Research Committee
22). If it is observed that 
the internal diameter of the coronary arteries in toddlers of 
five years old or less was over 3 mm or it was more than the 
diameter of adjacent vessels, it was defined as the dilatation 
of coronary arteries. If it was over 8 mm, it was classified as a 
giant aneurysm.
Right after the diagnosis was made, a high­dose of immu­
noglobulin (2 g/kg) was intravenously injected for over 12 
hours and a high­dose of aspirin (50 to 100 mg/kg) was ad­
ministered to all patients at the same time. The antibiotics 
were not used in all patients. Once 24 hours had passed after 
the fever subsided, a low­dose of aspirin (3 to 5 mg/kg) was 
administered for up to three months which was considered the 
recovery period. We considered the response of treatment with 
duration of fever after treatment, coronary artery le  sion and 
need of high­dose intravenous immunoglobulin re  treatment. 
Two groups were compared using the chi­square test and 
Student’s t­test with IBM SPSS ver. 19.0 (IBM Co., Armonk, 
NY, USA) for statistics. All values with P<0.05 were considered 
statistically significant.
Results
The pyuria group contained 40 patients (male 26, female 14) 
and accounted for 30.1% of total patients. The ratio of male to 
female was 1.9:1 and was not significant (P=0.374). In terms 
of the age of patients, the average age in the pyuria group was 
38 months (range, 3 to 85 months) and the average age in the 
control group was 35.7 months (range, 3 to 130 months). There 
was no significant difference (P=0.600) (Table 1).
As shown in Table 2, the number of white blood cells did 
not show any significant difference through the blood tests 
(P=0.107). However, the ESR and CRP were significantly high 
in the pyuria group (P=0.016, and 0.000, respectively). There 
was no difference between the two groups in serum sodium, 
potassium, total protein, albumin, B­type natriuretic peptide, 
AST, and osmotic pressure (P>0.05), but ALT was significantly 
higher in the group of pyuria (P=0.043). The creatinine 
clearance in pyuria group was 123.9±36.6 mL/min/1.73 m
2 and 
was 132.1±33.6 mL/min/1.73 m
2 in control group. There was no 
difference between the two groups (P=0.226) (Table 2).
Table 1. Characteristics of patients  
Characteristic Patient with pyuria 
(n=40)
Patient without pyuria 
(n=93) P value
Age (mo) 37±23 35±23 0.600
Gender (male/female) 26/14 56/37 0.374
Weight (kg) 14.7±4 13.7±7 0.40515 http://dx.doi.org/10.3345/kjp.2013.56.1.13
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Urine tests showed a total of six patients (the pyuria group 
had 3 patients and the control group had 3 patients) who had 
microscopic hematuria. However, it was not a statistically 
significant difference due to the low number of patients. The 
pyuria group showed the significantly high values in urine 
osmolality, potassium and creatinine (P=0.012, P=0.014, and 
P=0.001, respectively). However, total protein and the ratio 
of creatinine to total proteins in urine showed no significant 
difference between the two groups (P=0.256). The ratio of 
urine β2­MG calibrated by creatinine was 0.77±1.7 mg/g 
creatinine in the pyuria group and 0.63±1.5 mg/g creatinine in 
the control group (P= 0.741) (Table 3). 
In the case of showing the abnormality of coronary art­
eries on transthoracic echocardiography, the pyuria group 
contained 8 patients (20%) and the control group contained 
11 patients (11.8%). There was no statistically significant dif­
ference (P=0.269). The case of the giant aneurysm in which 
coronary arteries dilated to over 8 mm was not shown in the 
two groups (Table 4). 
There was no statistically significant difference in the 
duration of fever before treatment between two groups (P= 
0.187). The duration of the fever after treatments on the acute 
Table 2. Laboratory data of patients
Variable Patient with pyuria (n=40) Patient without pyuria (n=93) P value
White blood cell count (/μL) 15,844±4,844 14,170±5,709 0.107
Hemoglobin (g/dL) 11.4±1.2 11.6±1.0 0.633
Platelet (k/μL) 414±132 429±167 0.621
ESR (mm/H) 73.3±33.2 58.4±32.0 0.016
C-reactive protein (mg/dL) 11.3±6.8 6.7±5.7 0.000
Serum Na (mEq/L) 138.4±4.0 138.4±2.7 0.997
Serum K (mEq/L) 4.3±0.5 4.4±0.5 0.340
Serum BUN (mg/dL) 8.5±5.2 6.7±2.9 0.040
Serum creatinine (mg/dL) 0.4±0.1 0.3±0.1 0.012
Total protein (g/dL) 8.1±10.4 8.0±10.4 0.999
Albumin (g/dL) 4.0±0.9 4.0±0.5 0.985
AST (IU/L) 94.9±110.1 62.4±88.1 0.073
ALT (IU/L) 116.5±107.6 74.8±107.8 0.043
Serum osmolality (mOsm) 284.8±10.3 287.3±17.8 0.414
Estimated Ccr (mL/min/1.73 m²) 123.9±36.6 132.1±33.6 0.226
Values are mean±standard error of the mean.
ESR, erythrocyte sedimentation rate; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ccr, creatinine clearance.
Table 3. Urinary findings of patients
Patient with pyuria (n=40) Patient without pyuria (n=93) P value
Patients with hematuria* 3 (7.5) 3 (3.4) 0.373
Urine Na (mEq/L) 46.4±69.4 51.1±53.2 0.673
Urine K (mEq/L) 42.3±25.1 29.6±27.5 0.014
Urine osmolality (mOsm) 500±248.9 383±238.0 0.012
Urine creatinine (mg/dL) 83.3±65.6 43.5±40.3 0.001
Urine total protein (g/g creatinine) 0.2±0.3 0.4±2.1 0.256
Urine β2-MG (mg/g creatinine) 0.7±1.7 0.6±1.5 0.741
Values are presented as number (%) or mean±standard error of the mean.
β2-MG, β2-microglobulin.
*Urine red blood cell >5/high power field.
Table 4. Response to Treatment
Patient 
with pyuria 
(n=40) 
Patient 
without pyuria
(n=93)
 P value
Duration of fever before treatment 3.8±1.8 4.3±1.9 0.187
Duration of fever after treatment 4.2±3.1 3.0±3.1 0.039
Retreatment of high dose IVIG 8 (20.0) 9 (10.2) 0.131
Patients with CAL 8 (20.0) 11 (11.8) 0.269
Values are presented as mean±standard error of the mean or number (%).
IVIG, intravenous immunoglobulin; CAL, coronary artery lesion.http://dx.doi.org/10.3345/kjp.2013.56.1.13
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phase was an average of 4.2 days in the pyuria group and an 
average of 3 days in the control group. It confirmed that the 
response to treatment was slower in the pyuria group com­
pared to the control group (P=0.039) (Table 4).
Discussion
Kawasaki disease is a systemic vasculitis which frequently 
occurs mainly in infants and toddlers 5 years old or less 
may show the various symptoms and findings by involving 
multiple organs. In general, abnormal findings on urine tests 
which occur due to the invasion into the renal urinary tract 
include sterile pyuria, hematuria and proteinuria. The most 
common finding is sterile pyuria. However, not many studies 
about the meaning of pyuria in Kawasaki disease have been 
conducted. In this study, patients with Kawasaki disease 
who received treatments are divided into two groups such 
as the pyuria group which showed pyuria on urine test upon 
admission to the hospital and the control group. Comparative 
analysis on clinical progress characteristics, response to 
treatment, blood tests and urine tests are conducted to identify 
the meaning of pyuria in the Kawasaki disease.
Therapy for the acute phase was carried out using high­dose 
immunoglobulin and high­dose aspirin therapy. The number 
of patients who were treated with high­dose immunoglobulin 
more than twice was eight in the pyuria group and nine in the 
control group. There was no significant difference (P=0.131). 
The duration of fever after the treatments on the acute phase 
showed that the response to treatment for the acute phase was 
slower in the pyuria group compared to the control group 
(P=0.039). In addition, ESR and CRP were significantly high in 
the pyuria group (P<0.001). The abnormality in liver function 
is sometimes mentioned as an indicator for the systemic 
inflammatory response of Kawasaki disease
22). In this study, 
the ALT of pyuria group was significantly higher than the 
control group. However, the AST did not show any significant 
differences.
All of these results showed that the inflammation response 
in patients with Kawasaki disease in the acute phase ac­
companying pyuria was more severe. The response to anti  ­
inflammatory treatment thus was considered slow. On this 
basis, we think that the presence of pyuria with Kawasaki 
disease in the acute phase reflects the severity of inflammation.
Currently, many studies about the invasion into renal uri­
nary tracts in Kawasaki disease have been underway. First 
of all, in order to prove the invasion into renal urinary tract 
in Kawasaki disease, we need to check the renal function of 
patients with Kawasaki disease. For this, we need to measure 
the accurate glomerular filtration rate. By far the most com­
monly used methods are to calculate the glomerular filtration 
rate by measuring creatinine in blood and urine, and urine 
volume. However, since creatinine is influenced by age, mu­
scle mass and food intake, it has a disadvantage to reflect 
the glomerular filtration rate inaccurately. Therefore, there 
are continuing debates about other indicators to measure 
the glomerular filtration
23,24). Cystatin­C (Cys­C) is widely 
being used now as an indicator to reflect the renal function 
relatively accurate without the limitation of age, muscle 
mass, and protein intakes compared to creatinine
25). However, 
since it has been known that Cys­C is also affected by body 
composition
26) and the increase of CRP3
27), debates are still 
going on. Other indicators which are being studied include 
neutrophil gelatinase associated lipocalin
28,29) and kidney 
injury molecule­1
30). Although it is known that these methods 
sensitively predict the renal deterioration in a blood and urine 
test, they are less cost effective.
β2­MG which was used in this study has the implication in 
both blood and urine tests. Since it is a small globular protein 
with the molecular weight of 11,800 Da, it can pass relatively 
freely through the renal glomerular basement membrane 
and the most of them are absorbed through the proximal 
tubule. Thus, only a small portion is excreted if renal tubular 
function is normal
31,32). Since β2­MG in urine can be mea­
sured with noninvasive and easy methods, it can be used to 
evaluate the maturation of the renal tubule in infants
33). In 
case of a particular nephrotoxicity, the faster abnormal find­
ings are shown in nephrotoxicity caused by antibiotics of 
aminoglycosides compared to serum creatinine
34). It is being 
used as a useful indicator to check the function of renal uri­
nary tract. Ohta et al.
35) reported the possibility of renal 
involvement by the increase of interleukin­6, N­acetyl­β­D­
glucosaminidase in urine of patients with Kawasaki disease. 
In this study, urinary β2­MG which is calibrated by urinary 
creatine are high in both groups. This is the result with which 
we can infer the damage on renal function in most patients 
with Kawasaki disease.
Elevated levels of both BUN and creatinine in blood can 
be used as another indicator to imply the significant damage 
on renal function, but the elevated level of both BUN and 
creatinine were not observed in this study. BUN was higher 
in the pyuria group. It may not be due to the damage on renal 
function but it is thought to be caused by dehydration due to 
high fever and anorexia. In addition, in order to deter  mine the 
presence or absence of proteinuria, a urinary stick test and the 
ratio of protein and creatinine in urine were mea  sured, but 
there was no significant difference between the two groups. 
Schwartz formula
21) which is widely used for children is used 
to calculate creatinine clearance. It was also no difference 
between the two groups.17 http://dx.doi.org/10.3345/kjp.2013.56.1.13
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Besides blood and urine tests, there are some reports to 
confirm the invasion of renal parenchyme in Kawasaki dis­
ease through radiological tests. Nardi et al.
13) conducted the 
renal ultrasonography on four patients out of seven with 
Kawasaki disease showing hematuria, proteinuria and pyuria 
and confirmed the findings of increased cortical echogenicity, 
enlarged kidney and enhanced corticomedullary differen­
tiation. Wang et al.
36) conducted technetium­99m­dimer  cap­
tosuccinic acid renal scintigraphy single photon emission 
computed tomography and confirmed the renal scarring 
caus  ed by inflammation in 26 patients (52%) out of 50 patients 
with Kawasaki disease. In this study, radiological tests were 
not added, but we could estimate the decrease of renal func  tion 
due to the increase of urinary β2­MG and we need to develop a 
more desirable indicators to replace the creatinine in blood and 
urine in order to determine the renal involvement of Kawasaki 
disease.
In conclusion, we found that patients with Kawasaki dis­
ease with pyuria have more severe inflammatory response 
in the acute phase and the therapeutic response is slower as 
well. Therefore, more careful observations and tracking the 
clinical progress including complications caused by invasion 
of renal parenchyma in patients with Kawasaki disease and 
the additional research will be needed in the future.
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